Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo.

@article{Wang2010DihydroartemisininIN,
  title={Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo.},
  author={Shuang-jia Wang and Yue Gao and Hua Chen and Rui Kong and HongChi Jiang and Shang-ha Pan and Dongbo Xue and Xue-wei Bai and Bei Sun},
  journal={Cancer letters},
  year={2010},
  volume={293 1},
  pages={99-108}
}
Gemcitabine is currently the best known chemotherapeutic option available for pancreatic cancer, but the tumor returns de novo with acquired resistance over time, which becomes a major issue for all gemcitabine-related chemotherapies. In this study, for the first time, we demonstrated that dihydroartemisinin (DHA) enhances gemcitabine-induced growth inhibition and apoptosis in both BxPC-3 and PANC-1 cell lines in vitro. The mechanism is at least partially due to DHA deactivates gemcitabine… CONTINUE READING